Takeda Pharmaceutical Co Ltd ADR (TAK)

14.58
+0.22(+1.53%)
After Hours
14.67
+0.09(+0.62%)
- Real-time Data
  • Volume:
    1,210,362
  • Day's Range:
    14.37 - 14.60
  • 52 wk Range:
    12.28 - 15.36
High dividend Yield

Dividend yield shows how much a company pays its shareholders in dividends annually per dollar invested. It reflects how much an investor will earn aside from any capital gains in the stock.

TAK Overview

Prev. Close
14.36
Day's Range
14.37-14.6
Revenue
3.27T
Open
14.37
52 wk Range
12.28-15.36
EPS
137.17
Volume
1,210,362
Market Cap
44.91B
Dividend (Yield)
0.607
(4.16%)
Average Vol. (3m)
3,028,204
P/E Ratio
29.12
Beta
0.75
1-Year Change
7.76%
Shares Outstanding
1,545,364,083
Next Earnings Date
Feb 02, 2023
What is your sentiment on Takeda Pharma ADR?
or
Market is currently closed. Voting is open during market hours.

Takeda Pharmaceutical Co Ltd ADR News

Takeda Pharmaceutical Co Ltd ADR Analysis

Takeda Pharmaceutical Co Ltd ADR Company Profile

Takeda Pharmaceutical Co Ltd ADR Company Profile

Employees
47347

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., ZEDIRA GmbH, and Dr. Falk Pharma GmbH, as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuyStrong BuyStrong BuySell
Technical IndicatorsBuyStrong BuyStrong BuyStrong BuySell
SummaryNeutralStrong BuyStrong BuyStrong BuySell
  • buy now at $14.4 and wait for 1~2 month return to $16
    0
    • Which is P/E Ratio of TAK?
      0
      • PE Ratio (TTM) 15.44 from another source
        0
    • What's going on? I thought this share wll be 12 $
      2
      • what happened to the FDA decision 🤔
        0
        • FDA decision tommorrow
          0
          • Dividend yield shows as 1.22 (8.16%), I believe this is incorrect information as both NasdaqCom and Finviz + Yahoo Finance show a Yield of  4.13% and 4.84% respectively  - I don't understand why so much incongruence between sources, is anyone able to explain? Thanks!
            0
            • could be related to the way it is calculated (taking into account the last available price vs average of last 12months)
              0
          • ARK bought 1.2 Million yesterday
            0
            • this is going up..volume doubled in the last two days
              0
              • What's going on guys?
                0
                • It's going to 21$ soon
                  0